Search research articles
Contact Us
Filters
Showing results (531-540 of 652) with videos related to
Page
of 66
Sort By:
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Leukemia
|
May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
BMC Cancer
|
March 30, 2013
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
George Fountzilas, Urania Dafni, Mattheos Bobos, et al.
Haematologica
|
October 21, 2016
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Monique C Minnema, Eva Kimby, Shirley D'Sa, et al.
Blood Cancer Journal
|
March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Eirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Annals of Hematology
|
June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Ivan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 7, 2024
Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
Arnaud Jaccard, Frank Bridoux, Wilfried Roeloffzen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, et al.
The Lancet. Haematology
|
October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
Jesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 20, 2024
VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)
Efstathios Kastritis, Meral Beksac, Sorina Nicoleta Badelita, et al.
Page
of 66
Search research articles
Search
Showing results (531-540 of 652) with videos related to
Sort By:
Page
of 66
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Leukemia
|
May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
BMC Cancer
|
March 30, 2013
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
George Fountzilas, Urania Dafni, Mattheos Bobos, et al.
Haematologica
|
October 21, 2016
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Monique C Minnema, Eva Kimby, Shirley D'Sa, et al.
Blood Cancer Journal
|
March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Eirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Annals of Hematology
|
June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Ivan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 7, 2024
Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
Arnaud Jaccard, Frank Bridoux, Wilfried Roeloffzen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, et al.
The Lancet. Haematology
|
October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
Jesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 20, 2024
VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)
Efstathios Kastritis, Meral Beksac, Sorina Nicoleta Badelita, et al.
Page
of 66